Patents by Inventor Hans Menssen

Hans Menssen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF AN ERK INHIBITOR FOR THE TREATMENT OF MYELOFIBROSIS
    Publication number: 20240000777
    Abstract: The invention relates to the use of an ERK inhibitor in the treatment of myelofibrosis (MF). The invention also relates to a pharmaceutical combination comprising a) an ERK inhibitor and b) at least one further therapeutic agent, preferably ruxolitinib or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 7, 2021
    Publication date: January 4, 2024
    Inventors: Sime BRKIC, Hans MENSSEN, Sara MEYER, Thomas RADIMERSKI, Simona STIVALA
  • USE OF AN ERK INHIBITOR FOR THE TREATMENT OF MYELOFIBROSIS
    Publication number: 20230372334
    Abstract: The invention relates to the use of an ERK inhibitor in the treatment of myelofibrosis (MF).
    Type: Application
    Filed: October 7, 2021
    Publication date: November 23, 2023
    Inventors: Sime BRKIC, Hans MENSSEN, Sara MEYER, Thomas RADIMERSKI, Simona STIVALA
  • COMBINATION COMPRISING A TIM-3 INHIBITOR AND A HYPOMETHYLATING AGENT FOR USE IN TREATING MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA
    Publication number: 20230058489
    Abstract: Combination therapies comprising TIM-3 inhibitors are disclosed. The combinations can be used to treat cancerous conditions and disorders, including hematologic cancers.
    Type: Application
    Filed: January 15, 2021
    Publication date: February 23, 2023
    Inventors: Hans MENSSEN, Mikael RINNE, Kamel MALEK
  • USE OF AN MDM2 INHIBITOR FOR THE TREATMENT OF MYELOFIBROSIS
    Publication number: 20220331318
    Abstract: The invention relates to the use of an MDM2 inhibitor in the treatment of myelofibrosis (MF). The invention also relates to a pharmaceutical combination comprising a) an MDM2 inhibitor and b) at least one further therapeutic agent, preferably ruxolitinib or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 14, 2020
    Publication date: October 20, 2022
    Inventors: Asa Eliasson, Nelson Guerreiro, Christophe Meille, Hans Menssen, K Gary J Vanasse, Monika Wroclawska
  • USE OF HIGH-AFFINITY, LIGAND-BLOCKING, HUMANIZED ANTI-T-CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN-3 (TIM-3) IGG4 ANTIBODY FOR THE TREATMENT OF MYELOFIBROSIS
    Publication number: 20220306737
    Abstract: The invention relates to the use of an anti-TIM-3 antibody molecule in the treatment of myelofibrosis (MF). The invention also relates to a pharmaceutical combination comprising a) an anti-TIM-3 antibody molecule and b) at least one further therapeutic agent, preferably ruxolitinib or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 14, 2020
    Publication date: September 29, 2022
    Inventors: Asa Eliasson, Hans Menssen, K Gary J Vanasse, Monika Wroclawska
  • USE OF an anti-P-selectin antibody
    Publication number: 20210002374
    Abstract: The invention relates to the use of an anti-P-selectin antibody or binding fragment thereof, suitably crizanlizumab or a binding fragment thereof in the treatment of myelofibrosis (MF). The invention also relates to a pharmaceutical combination comprising a) an anti-P-Selectin antibody and b) at least one further therapeutic agent, preferably ruxolitinib or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 7, 2019
    Publication date: January 7, 2021
    Inventors: Shalini CHATURVEDI, Hans MENSSEN, Anna Rita Franco Migliaccio, Thomas Radimerski
  • Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
    Patent number: 9289470
    Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: March 22, 2016
    Assignee: PHILOGEN S.P.A.
    Inventors: Dario Neri, Hans Menssen, Andreas Menrad, Christoph Schliemann
  • COMBINATION OF AN ANTI-EDB FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART
    Publication number: 20140294723
    Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Applicant: PHILOGEN S.P.A.
    Inventors: Dario Neri, Hans Menssen, Andreas Menrad, Christoph Schliemann